The accusations against the drugmaker allege it violated the U.S. Foreign Corrupt Practices Act by bribing physicians in Greece, Vietnam, South Korea and China. Novartis will pay $234 million to the Department of Justice and $113 million to the Securities and Exchange Commission.
“Novartis AG’s subsidiaries profited from bribes that induced medical professionals, hospitals, and clinics to prescribe Novartis-branded pharmaceuticals and use Alcon surgical products, and they falsified their books and records to conceal those bribes,” DOJ Assistant Attorney General Brian Benczkowski said in a June 25 news release.
More articles on pharmacy:
Sanofi expedites its vaccine timeline, strikes $2.3B deal with Translate Bio
FDA urged to increase safety warnings on common diabetes drug
CVS to open 200 more drive-thru COVID-19 testing sites
